Overview

A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of Disitamb Vedotin combined with pyrotinib in HER2 positive early breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborator:
First Affiliated Hospital of Wenzhou Medical University